Disc Medicine (IRON), and Recursion Pharmaceuticals (RXRX) are making meaningful pipeline progress, with key clinical and regulatory catalysts ahead in 2026, Morgan Stanley said in a note Monday.

Detailed price information for Schrodinger Inc (SDGR-Q) from The Globe and Mail including charting and trades.

Artificial intelligence (AI) is poised to reshape pharmaceutical research by addressing some of the industry's most ...

In matters of work, school and even romance, we turn to A.I. chatbots. But what happens when the bots begin talking to one another? By Callie Holtermann Remember job applications? You know, you’d ...

Researchers make plea for much tighter security and safety after OpenAI briefly lost control of a group of AI models that ...

CRYPTO 2026 opens August 17 at UC Santa Barbara, marking the first major cryptology conference since NIST finalized its ...

The core mechanism leading to ASI is a feedback loop, which is the recently viral RSI (Recursive Self-Improvement): AI ...

With hyperscaler capital expenditure (capex) on track to surpass US$600 billion- $800 billion annually, several prominent ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...

Find out why the results may temper claims that recursive self-improvement is on the horizon. —Michelle Kim This summer has ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Thor #800 puts Sigurd Jarlson through the Serpent's ultimate trial, weaponless and desperate, as he begins the ultimate quest ...